Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • TA218
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Azacitidine is recommended as a treatment option for adults who are not eligible for haematopoietic stem cell transplantation and have:

  • intermediate-2 and high-risk myelodysplastic syndromes according to the International Prognostic Scoring System (IPSS) or

  • chronic myelomonocytic leukaemia with 10–29% marrow blasts without myeloproliferative disorder or

  • acute myeloid leukaemia with 20–30% blasts and multilineage dysplasia, according to the World Health Organization classification and

  • if the manufacturer provides azacitidine with the discount agreed as part of the patient access scheme.